|Table of Contents|

Association between systemic immunoinflammatory index and pathological complete response of neoadjuvant chemotherapy for breast cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 16
Page:
3019-3023
Research Field:
Publishing date:

Info

Title:
Association between systemic immunoinflammatory index and pathological complete response of neoadjuvant chemotherapy for breast cancer
Author(s):
YANG Yun; CHENG Fengfeng
Department of Breast Thyroid Surgery,the Second Affiliated Hospital of Guilin Medical College,Guangxi Guilin 541100,China.
Keywords:
systemic immunoinflammatory index; neoadjuvant chemotherapy for breast cancer; pathological complete response
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2024.16.014
Abstract:
Objective:To investigate the relationship between systemic immunoinflammatory index (SII) and pathological complete response of neoadjuvant chemotherapy in breast cancer.Methods:The clinicopathological data of 74 female breast cancer patients who received neoadjuvant chemotherapy and surgery in our hospital from July 2019 to December 2022 were retrospectively analyzed.χ2 test was used to conduct univariate analysis of clinicopathological data,and the factors with statistical significance were further analyzed by multivariate Logistic regression.Results:Univariate analysis confirmed that pathological complete response was related to SII,ER,PR and HER-2 status (P＜0.05),while multivariate analysis showed that HER-2 status and SII level were related to pathological complete response (P＜0.05).Compared with the low SII group,the high SII group was less likely to achieve pathological complete response.Compared with HER-2 negative state,HER-2 positive state had a higher probability of pathological complete response.Logistic regression model with SII value predicted that the AUC value of pathological complete response was 0.764.Conclusion:HER-2 status and SII level are independent predictors for evaluating the efficacy of neoadjuvant chemotherapy for breast cancer,and SII can be used as a supplement for pathological indicators to predict the efficacy of neoadjuvant chemotherapy.

References:

［1］FAN L,LI R,HUA B.Advances in the study of exosome-delivered non-coding RNA in breast cancer drug resistance［J］.Chinese Medical Frontiers Journal,2023,15(9):33-36.
［2］BRAY F,LAVERSANNE M,SUNG H，et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2024,74(3):229-263.
［3］RENEHAN AG,YEH HC,JOHNSON JA,et al.Diabetes and cancer (2):evaluating the impact of diabetes on mortality in patients with cancer［J］.Diabetologia,2012,55(6):1619-1632.
［4］WARD ZJ,ATUN R,HRICAK H,et al.The impact of scaling up access to treatment and imaging modalities on global disparities in breast cancer survival:a simulation-based analysis［J］.The Lancet Oncology,2021,22(9):1301-1311.
［5］ZHANG X,MI ZH.Identification of potential diagnostic and prognostic biomarkers for breast cancer based on gene expression omnibus［J］.World Journal of Clinical Cases,2023,11(27):6344-6362.
［6］JIA LP,BI LL,RUI FD.et al.A denoised multi-omics integration framework for cancer subtype classification and survival prediction［J］.Briefings in Bioinformatics,2023,9(5):5-6.
［7］KIM HM,KOO JS.Clinicopathologic characteristics of breast cancer according to the infiltrating immune cell subtypes［J］.International Journal of Molecular Sciences,2020,21(12):4438-4439.
［8］HOU W,YAO Q,NIU DF,et al.Clinicopathological characteristics related to Miller/Payne grading system of breast carcinoma after neoadjuvant therapy and establishment of novel prediction models［J］.Chinese Journal of Pathology,2022,51(8):743-748.
［9］艾勇彪，黄军，章书铭，等.影响青年乳腺癌患者新辅助化疗后病理完全缓解和预后的病理因素分析［J］.现代肿瘤医学，2022,30（10）：1781-1786. AI YB,HUANG J,ZHANG SM,et al.Analysis of the pathological factors influencing the pathological complete response and prognosis of young breast cancer patients after neoadjuvant chemotherapy［J］.Modern Oncology,2022,30（10）：1781-1786.
［10］MANTOVANI A,ALLAVENA P,SICA A,et al.Cancer-related inflammation ［J］.Nature,2008,454(7203):436-444.
［11］CLEMENCE P,MARC.Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy［J］.Breast Cancer Research and Treatment,2020,179(1):11-23.
［12］LIU C,SUN B,XU B,et al.A panel containing PD-1,IL-2Rα,IL-10,and CA15-3 as a biomarker to discriminate breast cancer from benign breast disease［J］.Cancer Management and Research,2018,10:1749-1761.
［13］CAO XH,MAO GX,XU RM,et al.Value of preoperative peripheral blood index detection in differential diagnosis and prognosis assessment of patients with breast cancer［J］.Journal of Nantong University,2022,42(6):523-526.
［14］MANDALIVA H,JONES M,OLDMEADOW C,et al.Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC):neutrophil to lymphocyte ratio (NLR),lymphocyte to monocyte ratio (LMR),platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI)［J］.Translational Lung Cancer Research,2019,8(6):886-894.
［15］LI QX,SHI DJ,LI L,et al.Relationship between body mass index,systemic immune-inflammatory index and endocrine drug resistance in Luminal breast cancer［J］.Chinese Journal of Experimental Surgery,2015,32(12):3156.
［16］CHEN L,KONG X,WANG Z,et al.Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy［J］.Journal of Cellular and Molecular Medicine,2020,24(5):2993-3021.
［17］WANG Y,LI Y,CHEN P,et al.Prognostic value of the pretreatment systemic immune-inflammation index (SII) in patients with non-small cell lung cancer:a meta-analysis［J］.Annals of Translational Medicine,2019,7(18):433.
［18］GAO Y,GUO W,CAI S,et al.Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected esophageal squamous cell carcinoma［J］.Journal of Cancer,2019,10(14):3188-3196.
［19］UZUNOGLU H,KAYA S.Does systemic immune inflammation index have predictive value in gastric cancer prognosis［J］.Northern Clinics of Istanbul,2023,10(1):24-32.
［20］YAMANOUCHI K,MAEDA S.The efficacy of inflammatory and immune markers for predicting the prognosis of patients with stage IV breast cancer［J］.Acta Medica Okayama,2023,77（1）:37-43.
［21］HA H,NAM AR,BANG JH,et al.Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy［J］.Oncotarget,2016,7(47):76604-76612.
［22］OGSTON KN,MILLER ID,PAYNE S,et al.A new histological grading system to assess response of breast cancers to primary chemotherapy:prognostic significance and survival［J］.Breast (Edinburgh,Scotland),2003,12(5):320-327.
［23］ABDEL RO.Validation of the 8th AJCC prognostic staging system for breast cancer in a population-based setting［J］.Breast Cancer Research and Treatment,2018,168(1):269-275.
［24］HAN X,LU H,TANG X,et al.Immunogenomic characterization in gastric cancer identifies microenvironmental and immunotherapeutically relevant gene signatures［J］.Immunity,Inflammation and Disease,2022,10(1):43-59.
［25］WALZ W,CAYABYAB FS.Neutrophil infiltration and matrix metalloproteinase-9 in lacunar infarction［J］.Neurochemical Research,2017,42(9):2560-2565.

［26］TAN KW,CHONG SZ,WONG FH,et al.Neutrophils contribute to inflammatory lymphangiogenesis by increasing VEGF-A bioavailability and secreting VEGF-D［J］.Blood,2013,122(22):3666-3677.
［27］JIANG L,LUAN Y,MIAO X,et al.Platelet releasate promotes breast cancer growth and angiogenesis via VEGF-integrin cooperative signal ling［J］.British Journal of Cancer,2017,117(5):695-703.
［28］MENTER DG,KOPETZ S,HAWK E,et al.Platelet "first responders" in wound response,cancer,and metastasis［J］.Cancer Metastasis Reviews,2017,36(2):199-213.
［29］MOHME M,RIETHDORF S,PANTEL K.Circulating and disseminated tumour cells-mechanisms of immune surveillance and escape［J］.Nature Reviews Clinical Oncology,2017,14(3):155-167.
［30］VELAEI K,SAMADI N,BARAZVAN B.Soleimani Rad J:Tumor microenvironment-mediated chemoresistance in breast cancer［J］.Breast (Edinburgh,Scotland),2016,30:92-100.
［31］SANCHEZ JI,HORSTMANN M,MENDEZ N,et al.Surgical interest of an accurate real-world prediction of primary systemic therapy response in HER2 breast cancers［J］.Annals of Surgical Oncology,2023,31(1):272-283.
［32］ERYILMAZ MK,MUTLU H,SALIM DK,et al.The neutrophil to lymphocyte ratio has a high negative predictive value for pathologic complete response in locally advanced breast cancer patients receiving neoadjuvant chemotherapy［J］.Asian Pacific Journal of Cancer Prevention Apjcp,2014,15(18):7737-7740.
［33］XUE LB,LIU YH,ZHANG B,et al.Prognostic role of high neutrophil-to-lymphocyte ratio in breast cancer patients receiving neoadjuvant chemotherapy:Meta-analysis ［J］.Medicine,2019,98(1):e13842.
［34］BUN A,HIGUCHI T,SATA A,et al.Prognostic significance of neutrophil-to-lymphocyte ratio in luminal breast cancers with low levels of tumour-infiltrating lymphocytes［J］.Anticancer Research,2020,4(5):2871-2880.
［35］LIU J,SHI Z,BAI Y,et al.Prognostic significance of systemic immune-inflammation index in triple-negative breast cancer［J］.Cancer Management and Research,2019,11:4471-4480.
［36］SUN Y,LI W,LI AJ,et al.Increased systemic immune-inflammation index independently predicts poor survival for hormone receptor-negative,HER2-positive breast cancer patients［J］.Cancer Management and Research,2019,11:3153-3162.

Memo

Memo:
广西自治区卫健委西医类自筹经费科研课题（编号：Z-C20220973）
Last Update: 1900-01-01